


Search [Get published](#)[Explore Journals](#)[Books](#)[About](#)[Login](#)

Menu ▼

---

## The Egyptian Journal of Neurology, Psychiatry and Neurosurgery

[About](#)[Articles](#)[Submission Guidelines](#)[About](#) ▼[Contact](#)[Editorial Board](#)

# About

## Aims and scope

*The Egyptian Journal of Neurology, Psychiatry and Neurosurgery*, the official publication of The Egyptian Society of Neurology, Psychiatry and Neurosurgery (ESNPN), is a peer-reviewed, open access journal publishing articles in the field of clinical neurosciences, including neurology, psychiatry and neurosurgery. The journal presents cutting edge research on technical and clinical studies of health, ethical and social issues in the field of clinical neurosciences.

---

## Open access

All articles published by the *The Egyptian Journal of Neurology, Psychiatry and Neurosurgery* are made freely and permanently accessible online immediately upon publication, without subscription charges or registration barriers. Further information about open access can be found [here](#).

As authors of articles published in the *The Egyptian Journal of Neurology, Psychiatry and Neurosurgery* you are the copyright holders of your article and have granted to any third party, in advance and in perpetuity, the right to use, reproduce or disseminate your article, according to the [SpringerOpen copyright and license agreement](#).

For those of you who are US government employees or are prevented from being copyright holders for similar reasons, SpringerOpen can accommodate non-standard copyright lines. Please [contact us](#) if further information is needed.

---

## Article-processing charges

*The Egyptian Journal of Neurology, Psychiatry and Neurosurgery* is supported through an agreement between Springer Nature and the Specialized Presidential Council for Education and Scientific Research (Government of Egypt), therefore author payable article processing charges do not apply.

author-payable article-processing charges do not apply.

---

## Indexing services

All articles published in *The Egyptian Journal of Neurology, Psychiatry and Neurosurgery* are included in:

- DOAJ
- EMBASE
- Emerging Sources Citation Index (ESCI)
- EBSCO Discovery Service
- OCLC
- Scopus
- Semantic Scholar
- Google Scholar
- Institute of Scientific and Technical Information of China
- Naver
- ProQuest-ExLibris Primo
- ProQuest-ExLibris Summon

The full text of all articles is deposited in [digital archives](#) around the world to guarantee long-term digital preservation. You can also access all articles published by SpringerOpen on [SpringerLink](#). We are working closely with relevant indexing services including PubMed Central and Web of Science (Clarivate Analytics) to ensure that articles published in *The Egyptian Journal of Neurology, Psychiatry and Neurosurgery* will be available in their databases when appropriate

---

## Peer-review policy

Peer-review is the system used to assess the quality of a manuscript before it is published. Independent researchers in the relevant research area assess

submitted manuscripts for originality, validity and significance to help editors determine whether the manuscript should be published in their journal. You can read more about the peer-review process [here](#).

*The Egyptian Journal of Neurology, Psychiatry and Neurosurgery* operates a double-blind peer-review system, where the reviewers do not know the names or affiliations of the authors and the reviewer reports provided to the authors are anonymous. Submitted manuscripts will generally be reviewed by two to three experts who will be asked to evaluate whether the manuscript is scientifically sound and coherent, whether it duplicates already published work, and whether or not the manuscript is sufficiently clear for publication. Reviewers will also be asked to indicate how interesting and significant the research is. The Editors will reach a decision based on these reports and, where necessary, they will consult with members of the Editorial Board.

---

## Citing articles in *The Egyptian Journal of Neurology, Psychiatry and Neurosurgery*

Articles in *The Egyptian Journal of Neurology, Psychiatry and Neurosurgery* should be cited in the same way as articles in a traditional journal. Because articles are not printed, they do not have page numbers; instead, they are given a unique article number.

Article citations follow this format:

Authors: Title. *Egypt J Neurol Psychiatry Neurosurg* [year], [volume number]: [article number].

e.g. Roberts LD, Hassall DG, Winegar DA, Haselden JN, Nicholls AW, Griffin JL: Increased hepatic oxidative metabolism distinguishes the action of Peroxisome Proliferator-Activated Receptor delta from Peroxisome Proliferator-Activated Receptor gamma in the Ob/Ob mouse. *Egypt J Neurol Psychiatry Neurosurg* 2009, **1**:115.

**1**:115 refers to article 115 from Volume 1 of the journal.

---

## Editorial policies

All manuscripts submitted to *The Egyptian Journal of Neurology, Psychiatry and Neurosurgery* should adhere to SpringerOpen's [editorial policies](#).

Once your article is accepted, it will be processed by production and published shortly afterwards. In some cases, articles may be held for a short period of time prior to publication. If you have any concerns or particular requirements please contact the Journal.

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

---

## Appeals and complaints

Authors who wish to appeal a rejection or make a complaint should follow the procedure outlined in the [BMC Editorial Policies](#).

---

## Benefits of publishing with SpringerOpen

### High visibility

*The Egyptian Journal of Neurology, Psychiatry and Neurosurgery's* open access policy allows maximum visibility of articles published in the journal as they are available to a wide, global audience.

### Speed of publication

*The Egyptian Journal of Neurology, Psychiatry and Neurosurgery* offers a fast publication schedule whilst maintaining rigorous peer review; all articles must be submitted online, and peer review is managed fully electronically (articles are distributed in PDF form, which is automatically generated from the submitted files). Articles will be published with their final citation after acceptance, in both fully browsable web form, and as a formatted PDF; the article will then be

available through *The Egyptian Journal of Neurology, Psychiatry and Neurosurgery* and SpringerOpen.

## Flexibility

Online publication in *The Egyptian Journal of Neurology, Psychiatry and Neurosurgery* gives you the opportunity to publish large datasets, large numbers of color illustrations and moving pictures, to display data in a form that can be read directly by other software packages so as to allow readers to manipulate the data for themselves, and to create all relevant links (for example, to PubMed, to sequence and other databases, and to other articles).

## Promotion and press coverage

Articles published in *The Egyptian Journal of Neurology, Psychiatry and Neurosurgery* are included in article alerts and regular email updates.

In addition, articles published in *The Egyptian Journal of Neurology, Psychiatry and Neurosurgery* may be promoted by press releases to the general or scientific press. These activities increase the exposure and number of accesses for articles published in *The Egyptian Journal of Neurology, Psychiatry and Neurosurgery*.

## Copyright

Authors of articles published in *The Egyptian Journal of Neurology, Psychiatry and Neurosurgery* retain the copyright of their articles and are free to reproduce and disseminate their work (for further details, see the [copyright and license agreement](#)).

For further information about the advantages of publishing in a journal from SpringerOpen, please click [here](#).

Submit manuscript

---

[Editorial Board](#)

---

[Sign up for article alerts and news from this journal](#)

---

## Associated Society

## Associated Society


[Contact](#)
[Terms and conditions](#)
[Jobs](#)
[Privacy statement](#)
[The Egyptian Society of Neurology, Psychiatry and Neurosurgery](#)
[Language editing for authors](#)
[Accessibility](#)
[Scientific editing for authors](#)
[Cookies](#)
**Annual Journal Metric**
[Leave feedback](#)

### Speed

[Follow SpringerOpen](#)

20 days to first decision for all manuscripts (Median)

35 days to first decision for reviewed manuscripts only (Median)



### Usage

 By using this website, you agree to our [Terms and Conditions](#), [California](#)

357,206 downloads (2021)

335 Annual Citations (2021)

[Privacy Statement](#), [Privacy statement](#) and [Cookies](#) policy. [Manage](#)
[cookies/Do not sell my data](#) we use in the preference centre.

### Social Media Impact

62 mentions

**SPRINGER NATURE**

 © 2023 BioMed Central Ltd unless otherwise stated. Part of [Springer Nature](#).

**Egyptian Knowledge Bank (EKB) Journals**


Egyptian Knowledge Bank  
بنك المعرفة المصري

 Visit our collection of [Egyptian journals](#).

ISSN: 1687-8329 (electronic)

# Editorial Board

## Editor-in-Chief

M. Ossama Abdulghani, *Ain Shams University, Egypt*

## Honorary Editors-in-Chief

Mohammad S Shehab, *Mansoura University, Egypt*

Hany Aref, *Ain Shams University, Egypt*

Ayman Nassef, *Ain Shams University, Egypt*

## Associate Editors

Ahmed M Abdelalim, *Cairo University, Egypt*

Khaled O Abdulghani, *Helwan University, Egypt*

## Managing Editors

Reda Badry, *Assiut University, Egypt*

Mona S Kamel, *Ministry of Health, Egypt*

Amr Elsamman, *Cairo University, Egypt*

Mona Kamel, *Ministry of Health, Egypt*

Imen Kacem, *Razi Hospital, Tunisia*

## Editorial Board Members

Ahmed Khalifa, *Damascus Hospital, Syria*

Ahmed Okasha, *Ain Shams University, Egypt*

Ali Benomar, *Rabat Specialized Hospital, Morocco*

Chokri Mhiri, *University of Sfax, Tunisia*

Dafin F Mureşanu, *University of Cluj-Napoca, Romania*

El-Sayed Tag-eldin, *Tanta University, Egypt*

Eman Khedr, *Assiut University, Egypt*

Farouk Talaat, *Alexandria University, Egypt*

Gharib Fawi, *Sohag University, Egypt*

Hamdy N El-Tallawy, *Assiut University, Egypt*

Jacques L De Reuck, *Lille University, Belgium*

James A Telmett, *Royal Adelaide University Hospital, Australia*

James F Toole, *Wake Forest University, USA*

Jean-Marc Leger, *University Hospital Pitié-Salpêtrière and University Pierre et*



*Marie Curie, France*

*Jeffrey L. Cummings, Cleveland Clinic Lou Ruvo Center for Brain Health, USA*

*Jun Kimura, University of Iowa, Japan*

*Magd F Zakareya, Ain Shams University, Egypt*

*Magdi Edarous, Zagazig University, Egypt*

*Maged Abdelnaseer, Cairo University, Egypt*

*Maurice Dahdaleh, Al-Khalidi Medical Center, Jordan*

*Mohammad S El-Tamawy, Cairo University, Egypt*

*Mohammad Al-Shehab, The Hashemite University, Jordan*

*Nathan B Fountain, University of Virginia, USA*

*Raad Shakir, Imperial College, UK*

*Riadh Gouider, University of Tunis, Tunisia*

*Saeed Bohlega, King Faisal Specialist Hospital, Saudi Arabia*

*Saher Hashem, Cairo University, Egypt*

*Salam Koussa, Saint-Joseph University, Lebanon*

*Saly El-Kholy, Cairo University, Egypt*

*Samia Ashour, Ain Shams University, Egypt*

*Samir Belal, National Institute of Neurology, Tunisia*

*Zuheir El-Kawi, King Faisal Specialized Hospital, Saudi Arabia*

*Ammar Ahmed, University of Khartoum, Sudan*

*Augustina Charway-Felli, African Academy of Neurology, Ghana*

*Emad Estemalik, Cleveland Clinic, USA*

*Hassan Hosny, Cairo University, Egypt*

*Nijedeka Okubadejo, University of Lagos, Nigeria*

*Oscar Arias-Carrión, Hospital General "Dr. Manuel Gea González", Mexico*

*Osheik Seidi, University of Khartoum, Sudan*

*Ragnar Stien, Ullevål University, Norway*

Submit manuscript

[Editorial Board](#)

[Sign up for article alerts and news from this journal](#)

## Associated Society


[Contact](#)
[Terms and conditions](#)
[Privacy statement](#)
[Journal for authors](#)
[Accessibility](#)
[Scientific editing for authors](#)
[Cookies](#)
[The Egyptian Society of Neurology, Psychiatry and Neurosurgery](#)
[Leave feedback](#)

### Altmetric



20 days to first decision for all manuscripts (Median)

35 days to first decision for reviewed manuscripts (Median)

By using this website, you agree to our [Terms and Conditions](#), [California Privacy Statement](#), [Privacy statement](#) and [Cookies policy](#). [Manage](#)

**Usage**  
[cookies/Do not sell my data](#) we use in the preference centre.

357,206 downloads (2021)

335 Altmetric mentions (2021)

**SPRINGER NATURE**

**Social Media Impact** 2023 Media Impact Ltd unless otherwise stated. Part of [Springer Nature](#).

62 mentions

### Egyptian Knowledge Bank (EKB) Journals



Egyptian Knowledge Bank  
 بنك المعرفة المصري

Visit our collection of [Egyptian journals](#).

ISSN: 1687-8329 (electronic)

Limited data are available on the frequency of carotid artery disease among cerebrovascular ischemic stroke (CVS) patients in south Egypt. The aim of the present study is to determine the prevalence and risk f...

Eman Khedr, Abeer A. Tony, Mohamed Habel and Ahmed Nasreldin

*The Egyptian Journal of Neurology, Psychiatry and Neurosurgery* 2021 57:128

Research | Published on: 20 September 2021

[Full Text](#) [PDF](#)

---

### Assessment of cognitive functions in patients with multiple sclerosis

About 40–70% of patients with multiple sclerosis (MS) develop cognitive impairment (CI) throughout their life. We aim to study the influence of MS on cognitive changes. This is a case–control study of fifty pa...

Tara A. Al-Falaki, Farqad B. Hamdan and Nawfal M. Sheahed

*The Egyptian Journal of Neurology, Psychiatry and Neurosurgery* 2021 57:127

Research | Published on: 17 September 2021

[Full Text](#) [PDF](#)

---

### Epidemiological profile of brain tumors in Cameroon: a retrospective study

Brain tumors represent group of neoplasms originating from intracranial tissues and the meninges. The aim of this study was to determine the epidemiological profile of brain tumors seen in a referral health ce...

Mathieu Motah, Daniel Gams Massi, Fabien Fouda Bekolo, Nkemontoh Akweseh Nju, Aurélien Ndoumbe, Mireille Moumi, Anne Sango, Paul Shu and Victor Eyenga

*The Egyptian Journal of Neurology, Psychiatry and Neurosurgery* 2021 57:126

Research | Published on: 17 September 2021

[Full Text](#) [PDF](#)

---

## High leukotriene B<sub>4</sub> serum levels increase risk of painful diabetic neuropathy among type 2 diabetes mellitus patients

Painful diabetic neuropathy is one of the most common complications of type 2 diabetes mellitus, with approximately 30–50% of people will experience diabetic neuropathy. Chronic hyperglycemia will cause an inf...

Kelvin Yuwanda, I Putu Eka Widyadharma, Dewa Putu Gde Purwa Samatra, I Made Oka Adnyana, Anna Marita Gelgel and I Komang Arimbawa

*The Egyptian Journal of Neurology, Psychiatry and Neurosurgery* 2021 57:125

Research | Published on: 15 September 2021

[Full Text](#) [PDF](#)

---

## Electrophysiological characteristics and anatomical differentiation of epileptic and non-epileptic myoclonus

Electrophysiological techniques have been used for discriminating myoclonus from other hyperkinetic movement disorders and for classifying the myoclonus subtype. This study was carried out on patients with dif...

Mohammad Abu-Hegazy, Azza Elmoungi, Eman Eltantawi and Ahmed Esmael

*The Egyptian Journal of Neurology, Psychiatry and Neurosurgery* 2021 57:124

Research | Published on: 14 September 2021

[Full Text](#) [PDF](#)

---

## A study of anxiety, depression and stress symptoms among Fayoum medical students during COVID-19 lockdown, Egypt

The widespread pandemic of COVID-19 virus carries not only physical hazards, but also major psychological effects especially among medical students. The aim was to investigate the psychological effects of COVI...

Mohamed R. Soltan, Shaimaa S. Soliman and Mariam E. Dawoud

*The Egyptian Journal of Neurology, Psychiatry and Neurosurgery* 2021 57:123

Research | Published on: 10 September 2021

Research | Published on: 10 September 2021

[Full Text](#) [PDF](#)

---

## Neurological sequelae of COVID-19: a review

The COVID-19 pandemic has produced a myriad of challenges, including identifying and treating neurological sequelae.

Christopher J. Peterson, Ashish Sarangi and Fariha Bangash

*The Egyptian Journal of Neurology, Psychiatry and Neurosurgery* 2021 57:122

Review | Published on: 8 September 2021

[Full Text](#) [PDF](#)

---

## Reply to Letter to Editor: Is SARS-CoV-2 responsible for relapses of Parkinson's disease?

Walaa A. Kamel, Ismail Ibrahim Ismail, Mohamed Ibrahim and Jasem Y. Al-Hashel

*The Egyptian Journal of Neurology, Psychiatry and Neurosurgery* 2021 57:121

Letter to the Editor | Published on: 8 September 2021

[Full Text](#) [PDF](#)

---

## Pathophysiology of SARS-CoV-2-associated ischemic stroke is variegated

Fulvio A. Scorza, Ana C. Fiorini and Josef Finsterer

*The Egyptian Journal of Neurology, Psychiatry and Neurosurgery* 2021 57:120

Letter to the Editor | Published on: 8 September 2021

[Full Text](#) [PDF](#)

---

## Cognitive impairment and depression in patients with relapsing–remitting multiple sclerosis depending on age and neuroimaging findings

Multiple sclerosis is an insidious, disabling, both physically and mentally, demyelinating disease of the central nervous system. This work aims to evaluate relationships between cognitive impairment in separa...

also developed by scimago:



SCIMAGO INSTITUTIONS RANKINGS

SJR

Scimago Journal &amp; Country Rank

Enter Journal Title, ISSN or Publisher Name

[Home](#)[Journal Rankings](#)[Country Rankings](#)[Viz Tools](#)[Help](#)[About Us](#)

## Egyptian Journal of Neurology, Psychiatry and Neurosurgery

### COUNTRY

[United States](#)Universities and research  
institutions in United States

### SUBJECT AREA AND CATEGORY

[Medicine](#)[Neurology \(clinical\)](#)[Psychiatry and Mental Health](#)[Surgery](#)[Neuroscience](#)[Neuroscience \(miscellaneous\)](#)

### PUBLISHER

[Springer Nature](#)

### H-INDEX

11

### PUBLICATION TYPE

[Journals](#)

### ISSN

11101083, 16878329

### COVERAGE

2009-2016, 2018-2021

### INFORMATION

[Homepage](#)[How to publish in this journal](#)

### SCOPE

The Egyptian Journal of Neurology, Psychiatry and Neurosurgery, the official publication of The Egyptian Society of Neurology, Psychiatry and Neurosurgery (ESNPN), is a peer-reviewed, open access journal publishing articles in the field of clinical neurosciences, including neurology, psychiatry and neurosurgery. The journal presents cutting edge research on technical and clinical studies of health, ethical and social issues in the field of clinical neurosciences.



Join the conversation about this journal



Quartiles

### FIND SIMILAR JOURNALS

options 1  
**BMC Neurology**

GBR

80%

similarity

2  
**Neurologia i Neurochirurgia**Polska  
POL

76%

similarity

3  
**Chinese Journal of  
Contemporary Neurology and**  
CHN

71%

similarity

4  
**Neurology Research  
International**  
USA

71%


similarity

5  
**Türk Noroloji Dergisi**

TUR

69%

similarity



← Show this widget in your own website

Just copy the code below and paste within your html code:

```
<a href="https://www.scimagojr.com/journalsearch.php?q=17500155106&tip=...">
```

**SCImago Graphica**

Explore, visually communicate and make sense of data with our [new data visualization tool](#).



Metrics based on Scopus® data as of April 2022



Loading comments...

Developed by:



Powered by:



Follow us on @ScimagoJR

Scimago Lab, Copyright 2007-2022. Data Source: Scopus®

EST MODUS IN REBUS  
(Morales (Satire 1.1.106))

[Edit Cookie Consent](#)

RESEARCH

Open Access



# High leukotriene B4 serum levels increase risk of painful diabetic neuropathy among type 2 diabetes mellitus patients

Kelvin Yuwanda, I Putu Eka Widyadharma<sup>\*</sup> , Dewa Putu Gde Purwa Samatra, I Made Oka Adnyana, Anna Marita Gelgel and I Komang Arimbawa

## Abstract

**Background:** Painful diabetic neuropathy is one of the most common complications of type 2 diabetes mellitus, with approximately 30–50% of people will experience diabetic neuropathy. Chronic hyperglycemia will cause an inflammatory process that will trigger an immune response included leukotrienes. Leukotriene B4 is associated with hemoglobin glycation levels. This study aimed to determine high serum leukotriene B4 levels and other factors as a risk factor for painful diabetic neuropathy in type 2 diabetes mellitus patient.

**Results:** Forty-two subjects with 22 cases (median age  $56.5 \pm 4.9$  years) and 20 controls (median age  $56.5 \pm 5.2$  years) group were collected. In bivariate analysis, significant factor for high risk PDN was high leukotriene B4 serum level (OR 5.10; 95% CI 1.34–19.4,  $p$  0.014). Meanwhile, insignificant factors were anti-diabetic drugs (OR 2.139; 0.62–7.37;  $p$  = 0.226), and duration of diabetes mellitus (OR 2.282; 0.56–9.25;  $p$  = 0.315). Independent risk factor was serum leukotriene B4 levels (OR 5.10; 95% CI 1.336–19.470;  $p$  = 0.017).

**Conclusions:** In this study, high leukotriene B4 serum levels increase the risk of painful diabetic neuropathy among type 2 diabetes mellitus. The leukotriene B4 may consider as a potential biomarker for early detection in high risk for PDN and early treatment.

**Keywords:** Diabetes mellitus, Painful diabetic neuropathy, Leukotriene B4 levels

## Background

Diabetes mellitus (DM) is one of the metabolic diseases with the feature of hyperglycemia, caused by the abnormalities in insulin secretion, insulin action, or both [1]. Untreated hyperglycemia for long periods can damage various organs of the body, such as cardiovascular disease, neuropathy, nephropathy, and eye disease [2]. One of the most common complications of DM is diabetic neuropathy [3].

Almost 30–50% of DM patients will suffer neuropathy [4]. The prevalence of populations suffer from Painful

Diabetic Neuropathy (PDN) is estimated to be 8–26% [5]. The incidence of PDN is estimated to be 17.8 per 100,000 people per year and increases with age in the United Kingdom [6]. Another literature found that the prevalence of PDN was 30.3%, consisting of 33.1% type 2 diabetes patients and 14.1% type 1 diabetes patients [7]. PDN might lead increase in the morbidity and mortality rate. DPN requires complex management once diagnosed, but beforehand, it should stress the importance of early screening for diagnosis [8].

Inflammatory mediators cause changes in the expression of sodium channels in nerve fibers that cause abnormal activation in sensory neurons. Those cause an increase in pain stimulus that reaches the spinal cord. In addition, the constant accumulation of nerve

<sup>\*</sup>Correspondence: eka.widyadharma@unud.ac.id  
Department of Neurology, Faculty of Medicine, Udayana University/  
Sanglah Hospital, Bali, Indonesia



C fibers causes an increase in release from inflammatory mediators such as transcription factors and nuclear factor-kappa B (NF- $\kappa$ B) [9]. Leukotrienes are inflammatory mediators that importantly play roles in acute and chronic inflammatory diseases. Leukotriene B4 (LTB4) that binds to leukotriene receptors (BLT)-1 is able to trigger inflammation, increase cytokine production, phagocytosis and mediate antimicrobial function [10].

Several kinds of research showed that LTB4 might consider as a diagnostic biomarker for inflammation cases of lymphedema, preeclampsia, obstructive pulmonary disease, and diabetic neuropathy [11–14]. However, regarding the authors' knowledge, LTB4 studies as a risk factor for PDN have never been done in Indonesia before. Therefore, the authors are attracted to conducting this research. This study aims to determine that high levels of LTB4 are a risk factor for diabetic neuropathy pain.

## Method

This research is an analytic observational study with a case control design conducted in the neurology polyclinic and diabetic center Sanglah General Hospital Denpasar. This research has obtained ethical clearance No:2969/UN14.2.2.VII.14/LP/2019 from Udayana University Faculty of Medicine/Sanglah General Hospital Research Ethics Committee and also has obtained written consent from patients to participate this study.

The sample subjects in this study were patients who were proven to have type 2 DM aged 45–64 years with (case group) or without (control group) PDN who underwent treatment at the neurology and diabetic center of Sanglah Hospital. The PDN in this study was defined as all neuropathic pain conditions suffered by DM patients as evidenced by a DN4 (Douleur Neuropathique 4 Questions) score  $\geq 4$  and met the inclusion criteria. DN4 is a questionnaire with interviews and medical examinations to screen for the presence of neuropathic pain [15]. All participants who are willing to be sampled in this study were full alert and not under any coercion.

Exclusion criteria in this study were: (1) type 2 DM patients with a diagnosis period of  $>5$  years [to avoid multifactorial causes other than type 2 DM]; (2) history of neuropathy due to other causes such as chronic kidney disease, chronic liver disease, chronic infection [Human Immunodeficiency Virus, leprosy], malignancy, mechanical nerve entrapment [carpal tunnel syndrome, cervical root syndrome]; (3) history of antiretroviral drugs, chemotherapy, estrogen hormone; (4) history of exposure to toxins such as alcohol, pesticides, mercury, organophosphates and lead; (5) obesity; (6) dyslipidemia; and (7) moderate-to-severe depression [BDI(Beck Depression Inventory)-II result  $\geq 20$ ]. The BDI-II was performing to

exclude possible confounding of subjectively obtained PDN assessments.

All samples that met the inclusion criteria were collecting by convenience sampling technique to reach the expected sample size. With the patient's consent, blood samples for the examination of LTB4 levels were taken and processed using the ELISA method with the cut-off of  $\leq 63.5$  pg/mL as a norm value [15]. All data were checked for completeness, and responses were coded and entered into the Statistical Package for the Social Sciences (SPSS) software (version 25; SPSS Inc., Armonk, NY, USA) for windows. Then results were tabulated, graphically, and statistically analysed. Descriptive analyses were showed in both groups regarding categorical or continuous variables. Bivariate analysis were made using the Chi-squared test. Meanwhile, multivariate logistic regression model was utilized to evaluate the independent risk factors of PDN.  $P$  value  $\leq 0.05$  was considered significant.


## Result

Subjects on both groups were dominated by males ( $n=71.4\%$ ) and 56.5 years as the median age. As much as 54.8% of subjects used oral anti-diabetic drugs. 71.4% of subjects suffered from diabetes for  $\leq 2$  years. LTB4 value obtained with a range of 12–124 ng/mL, with a median of 43.80 ng/mL. The characteristics of research subjects from both groups shown in Table 1.

The ROC curve (Fig. 1) shows that the LTB4 value has a pretty good diagnostic value, because the curve is above the 50% line. The AUC value obtained from the ROC method is 84.2% (0.73–0.96%,  $p=0.001$ ) which statistically indicates sufficient diagnostic strength. The results of the ROC coordinates show that the LTB4 cutoff value of 40.89 ng/mL used in this study has a sensitivity

**Table 1** Characteristics of research subject

Demographic profile	Case $n$ (%)	Control $n$ (%)
Age median $\pm$ SD (years old)	56.5 $\pm$ 4.9	56.5 $\pm$ 5.2
Gender		
Male	16 (72.7)	14 (70.0)
Female	6 (27.3)	6 (30.0)
Duration of DM		
$< 2$ years	14 (63.6)	16 (80.0)
2–5 years	8 (36.4)	4 (20.0)
Type of diabetic drugs		
Oral	14 (63.6)	9 (45.0)
Insulin	8 (36.4)	11 (55.0)
LTB 4 serum		
Normal	5 (22.7)	12 (60.0)
High	17 (77.3)	8 (40.0)



of 95.7% and a specificity of 80.3%. The research data were divided into two group; high serum LTB4 group at  $\geq 40.89$  pg/mL and normal serum LTB4 at  $< 40.89$  pg/mL.

The analysis showed a significant correlation between high serum LTB4 levels with PDN in type 2 DM patients with OR 5.10 (1.34–19.4;  $p=0.014$ ) which means high serum LTB4 levels in type 2 DM patients increased risk 5.10 times to experience PDN compared with DM patients with low serum LTB4 levels. This can be shown in Table 2.

This study also sought a relationship between PDN in patients with type 2 diabetes with other variables that might be influential. In this study a bivariate analysis was carried out between diabetic neuropathy pain in patients with type of anti-diabetic drugs, and duration of anti-diabetic drugs in Table 3. The hypothesis test used was a paired categorical comparative test with the Chi-square method. Of all the variables, there were no statistically significant variables related to PDN in patients with DM.

To find out the variables that are independent risk factors for the occurrence of PDN in patients with DM, a multivariate analysis using logistic regression method

**Table 3** Bivariate analysis of other variables and painful diabetic neuropathy on type 2 DM patients

Variable	Case n (%)	Control n (%)	OR (CI 95%)	p
Anti-diabetic drug type				
Insulin	8 (42.1)	11 (57.9)	2.139 (0.62–7.37)	0.226
Oral	14 (60.9)	9 (39.1)		
DM duration				
< 2 years	14 (46.7)	16 (53.3)	2.286 (0.56–9.25)	0.315
2–5 years	8 (66.7)	4 (33.3)		

**Table 4** Multivariate logistic regression analysis

Characteristics	Adjusted OR	CI 95%	p
Step 1			
High LTB4 level	10.431	1.056–102.997	0.045
Anti-diabetic drug type	0.394	0.041–3.782	0.420
Step 2			
High LTB4 level	5.10	1.336–19.470	0.017*

was performed. The variables included in the multivariate analysis were serum LTB4 levels and the type of oral anti diabetic drug which in the bivariate analysis obtained  $p$  values  $< 0.25$ . The complete data of multivariate analysis is presented in Table 4. From the multivariate analysis, it was found that the independent risk factor for the incidence of PDN in patients with DM was serum LTB4 levels with OR 5.10; 1.336–19.470;  $p=0.017$ .

## Discussion

This study found a significant relationship between high serum LTB4 levels and PDN in patients with DM. High serum LTB4 levels in DM patients significantly increased the risk of 5.10 times to suffer PDN compared with DM patients with low serum LTB4 levels (1.34–19.4;  $p=0.014$ ). Diabetes mellitus causes chronic low-grade inflammation and metabolic changes. This inflammation is triggered by various endogenous substances and causes sterile inflammation. This inflammation causes the release of arachidonic acid from leukocytes and arachidonic acid then metabolized into 5-HpETE (5-hydroperoxyeicosatetraenoic acid) and with the help of the 5-LO (5-lipoxygenase) enzyme becomes LTA4 (leukotriene

**Table 2** Bivariate analysis of LTB4 serum level and painful diabetic neuropathy on type 2 DM patients

Variable		Case n (%)	Control n (%)	OR (CI 95%)	p
Leukotriene B4 Serum level	High	17 (77.3)	8 (40.0)	5.10 (1.34–19.4)	0.014*
	Normal	5 (22.7)	12 (60.0)		

A4). LTA4 then metabolizes into LTB4 by LTA4 hydro-lase and LTB4 can bind to its specific receptor [16].

LTB4 can also work centrally on the occurrence of PDN. LTB4 binds to the BLT1 receptor expressed in the dorsal medulla of the spinal cord. This activation causes an increase in the activation of NMDA (*N*-methyl-D-aspartate) receptors through intracellular G protein, besides that LTB4 can cause PDN by activating NADPH (Nicotinamide adenine dinucleotide phosphate) oxidase which causes neuronal damage [17, 18].

Study conducted by Noguchi and colleagues found that type 2 DM patients with high serum LTB4 levels have higher risk of suffering from painful diabetic neuropathic compared to the low serum LTB4 levels. This finding is thought to be due to increased leukotriene synthesis in the spinal cord after peripheral nerve injury and this enzyme affects pain behavior especially diabetic neuropathy pain. In addition, lipooxygenase metabolites are also involved in the process of hyperalgesia in peripheral inflammation. LTB4 is released by immune cells such as neutrophils and has a nociceptive effect on peripheral inflammation [19].

Expression of 5-LO in spinal cord microglia and BLT-1 mRNA in spinal cord neurons increases when peripheral nerve injury occurs. These findings indicate that central sensitization after peripheral nerve injury associated with the role of LTB4. However, it is not yet known how LTB4 plays a role in excitation of neurotransmitters in the spinal cord's dorsal horn [20]. According to author's knowledge, there has been no similar study comparing the levels of leukotrienes B4 serum with diabetic neuropathic pain in DM patients, but there are several studies linking levels of inflammatory mediators such as NF- $\kappa$ B with the incidence of diabetic neuropathy in patients with DM [21].

Limitations in this study included a limited sample population, no electrophysiological examination was performed in all cases, and did not determine the minimum level of LBT4 that causes neuropathic pain.

## Conclusion

From this study it was assumed that high serum LTB4 levels is a risk factor for painful diabetic neuropathy in Type 2 Diabetes Mellitus. The examination of serum LTB4 levels can be considered as a parameter to determine the risk of neuropathic pain in people with type 2 diabetes, so that early management can be done. However, further research with bigger sample size and usage of electrophysiology is needed.

## Abbreviations

DM: Diabetes mellitus; PDN: Painful Diabetic Neuropathic; NF- $\kappa$ B: Nuclear factor-kappa B; LTB4: Leukotriene B4; BLT-1: Binds to leukotriene receptors-1;

HIV: Human Immunodeficiency Virus; BDI II: Beck Depression Inventory II; 5-HpETE: 5-Hydroperoxyeicosatetraenoic acid; 5-LO: 5-Lipoxygenase; LTA4: Leukotriene A4; NMDA: *N*-Methyl-D-aspartate; NADPH: Nicotinamide adenine dinucleotide phosphate.

## Acknowledgements

Not applicable.

## Authors' contributions

KY and IPEW conceived the original idea of this research and proof outline. KY wrote the manuscript with support, help and input from IPEW, DPGPS, IMOA, AMG, and IKA. KY collected the samples and input the data. KY with help from IPEW, DPGPS and IMOA analyzed the data. KY, AMG, and IKA also done the copyediting, proofreading and revised the final manuscript. All authors were involved in drafting the article or revising it critically for important intellectual content. All authors read and approved the final manuscript.

## Funding

The authors declared no financial support.

## Availability of data and materials

The data used and analysed during the current study are available from the corresponding author on reasonable request.

## Declarations

### Ethics approval and consent to participate

This research has obtained ethical clearance No:2969/UN14.2.2.VII.14/LP/2019 from Udayana University Faculty of Medicine/Sanglah General Hospital Research Ethics Committee and also has obtained written consent from patients to participate this study.

### Consent for publication

This research has obtained consent for publication.

### Competing interests

None (the authors declare that they have no competing interests).

Received: 16 June 2021 Accepted: 26 August 2021

Published online: 15 September 2021

## References

1. Kharroubi AT, Darwish HM. Diabetes mellitus: the epidemic of the century. *World J Diabetes*. 2015;6(6):850–67. <https://doi.org/10.4239/wjcd.v6.i6.850>.
2. International Diabetes Federation. IDF diabetes atlas. 7th ed. Brussels: International Diabetes Federation; 2015.
3. Tesfaye S, Boulton AJM, Dyck PJ, Freeman R, Horowitz M, Kempner P, et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. *Diabetes Care*. 2010;33(10):2285–93. <https://doi.org/10.2337/dc10-1303>.
4. Jambart S, Ammache Z, Haddad F, Younes A, Hassoun A, Abdalla K, et al. Prevalence of painful diabetic peripheral neuropathy among patients with diabetes mellitus in the Middle East region. *J Int Med Res*. 2011;39(2):366–77. <https://doi.org/10.1177/147323001103900204>.
5. Risson V, Nallagangula TK, Vasanthaprasad V. Incidence and prevalence of painful diabetic neuropathy and postherpetic neuralgia in major 5 European countries, the United States and Japan. *Value Health*. 2017;20(9):A547. <https://doi.org/10.1016/j.jval.2017.08.845>.
6. Reed C, Hong J, Novick D, Lenox-Smith A, Happich M. Incidence of diabetic peripheral neuropathic pain in primary care—a retrospective cohort study using the United Kingdom General Practice Research Database. *Pragmat Obs Res*. 2013;4:27–37. <https://doi.org/10.2147/POR.S49746>.
7. Aslam A, Singh J, Rajbhandari S. Prevalence of painful diabetic neuropathy using the Self-completed Leeds Assessment of Neuropathic Symptoms and Signs Questionnaire in a population with diabetes. *Can J Diabetes*. 2015;39(4):285–95. <https://doi.org/10.1016/j.jcjd.2014.12.007>.

8. Salmen T, Pietrosel VA, Hernest G, Chipier GV, Florea DE, Popa LM, et al. Early diagnosis of peripheral diabetic neuropathy-something old that should always be considered something new. *Rom J Diabetes Nutr Metab Dis*. 2020;27(2):99–103. <https://doi.org/10.46389/rjd-2020-1017>.
9. Omoigui S. The biochemical origin of pain-proposing a new law of pain: the origin of all pain is inflammation and the inflammatory response. *Med Hypotheses*. 2007;69(1):70–82. <https://doi.org/10.1016/j.mehy.2006.11.028>.
10. Bhatt L, Roinestad K, Van T, Springman EB. Recent advances in clinical development of leukotriene B4 pathway drugs. *Semin Immunol*. 2017;33:65–73. <https://doi.org/10.1016/j.smim.2017.08.007>.
11. Herrada AA, Mejias C, Lazo-Amador R, Olane-Briones A, Lara D, Escobedo N. Development of new serum biomarkers for early lymphedema detection. *Lymphat Res Biol*. 2020;18(2):136–45. <https://doi.org/10.1089/lrb.2019.0008>.
12. Lantos LL, Wertaschnigg D, Rolnik DL, Costa FDS, Syngelaki A, Dimitriadis E, et al. Serum leukotriene B4 acid in the prediction of pre-eclampsia. *Placenta*. 2021;103:76–81. <https://doi.org/10.1016/j.plasenta.2020.10.007>.
13. Seggev JS, Thornton WH, Edes TE. Serum leukotriene B4 levels in patients with obstructive pulmonary diseases. *Chest*. 1991;99(2):289–91. <https://doi.org/10.10378/chest.99.2.289>.
14. Neves JAJ, Matos MRD, Ramalho T, Santos-Bezerra DP, Cavalcante CDGD, Peixoto RDA, et al. Increased leukotriene B4 plasma concentration in type 2 diabetes individuals with cardiovascular autonomic neuropathy. *Diabetol Metab Syndr*. 2020. <https://doi.org/10.1186/s13098-020-00606-3>.
15. Spallone V, Greco C. Painful and painless diabetic neuropathy: one disease or two? *Curr Diab Rep*. 2013;13:533–49. <https://doi.org/10.1007/s11892-013-0387-7>.
16. Tahalli R, Zarini S, Sheibani N, Murphy RC, Gubitosi-Klug RA. Increased synthesis of leukotrienes in the mouse model of diabetic retinopathy. *Invest Ophthalmol Vis Sci*. 2010;51(3):1699–708. <https://doi.org/10.1167/iops.09-3557>.
17. Yagihashi S, Mizukami H, Sugimoto K. Mechanism of diabetic neuropathy: where are we now and where to go? *J Diabetes Invest*. 2010;2(1):18–32. <https://doi.org/10.1111/j.2040-1124.2010.00070.x>.
18. Allison DJ, Thomas A, Beaudry K, Ditor DS. Targeting inflammation as a treatment modality for neuropathic pain in spinal cord injury: a randomized clinical trial. *J Neuroinflamm*. 2016;13(1):152. <https://doi.org/10.1186/s12974-016-0625-4>.
19. Noguchi K, Okubo M. Leukotrienes in nociceptive pathway and neuropathic/inflammatory pain. *Biol Pharm Bull*. 2011;34(8):1163–9. <https://doi.org/10.1248/bpb.34.1163>.
20. Kiyoyuki Y, Taniguchi W, Okubo M, Yamanaka H, Kobayashi K, Nishio N, et al. Leukotriene enhances NMDA-induced inward currents in dorsal horn neurons of the rat spinal cord after peripheral nerve injury. *Mol Pain*. 2015;11:53. <https://doi.org/10.1186/s12990-015-0059-5>.
21. Suryavanshi SV, Kulkarni YA. NF- $\kappa$ B: a potential target in the management of vascular complications of diabetes. *Front Pharmacol*. 2017;8:798. <https://doi.org/10.3389/fphar.2017.00798>.

## Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Submit your manuscript to a SpringerOpen<sup>®</sup> journal and benefit from:**

- Convenient online submission
- Rigorous peer review
- Open access: articles freely available online
- High visibility within the field
- Retaining the copyright to your article

---

Submit your next manuscript at ► [springeropen.com](https://www.springeropen.com)